

Short Versus Long Antiplatelet Therapy After TAVI

NCT06518317

Status	RECRUITING
Phase	Phase 3
Sponsor	University Hospital, Caen
Enrollment	1,400 participants

Key Eligibility Criteria

Inclusion (9)

- Age ≥ 18
 - Male or, post-menopausal -with no menses for 12 months without an alternative medical cause- or permanently sterilized -hysterectomy, bilateral salpingectomy or bilateral oophorectomy- female
 - Successful transfemoral TAVI for symptomatic aortic stenosis as defined by VARC-33
 - Successful access, delivery of the device, and retrieval of the delivery system
 - Correct positioning of a single prosthetic heart valve into the proper anatomical location
- ... and 4 more (see full listing online)

Exclusion (17)

- Un-successful TAVI defined by the absence of any of the above-mentioned criteria defining successful TAVI3
 - Alternative non-femoral-approach TAVI: apical, direct trans-aortic, subclavian, axillary or carotid approaches
 - TAVI for other indications than aortic stenosis (pure aortic regurgitation)
 - Valve in valve TAVI
 - Any indication for long term antiplatelet therapy: (e.g. coronary artery disease, cerebrovascular disease, peripheral arterial disease...) at any time prior to randomization
- ... and 12 more (see full listing online)

Locations (1 total)

Caen University Hospital, Caen, France